Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
<!-- Name:DistributionId Value:8838779 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Browsing Tag
Fulcrum Therapeutics
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and…
<!-- Name:DistributionId Value:8782709 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<!-- Name:DistributionId Value:8747281 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
― FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ―― Completed enrollment in 6 mg and 2 mg dose cohorts of the Phase 1b trial of FTX-6058 in SCD; enrollment ongoing in 12 mg dose cohort ――…
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced…
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod…
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular…
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial…
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports proof-of-concept that FTX-6058 is a novel oral HbF inducer - FTX-6058 was generally well…
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with…
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from the ongoing 6 mg dose cohort of…
Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for…
Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial Live webcast March 24, 2022 at 10:00am ET CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq:…
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced…